Get the Stockscreener App
2.80
0.36%
-0.01
Pre-market:
2.76
-0.04
-1.43%
Equillium Inc stock is traded at $2.80, with a volume of 362.03K.
It is down -0.36% in the last 24 hours and up +28.44% over the past month.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
See More
Previous Close:
$2.81
Open:
$2.84
24h Volume:
362.03K
Relative Volume:
0.55
Market Cap:
$177.03M
Revenue:
$4.39M
Net Income/Loss:
$-22.40M
P/E Ratio:
-5.4923
EPS:
-0.5098
Net Cash Flow:
$-22.79M
1W Performance:
+1.08%
1M Performance:
+28.44%
6M Performance:
+129.51%
1Y Performance:
+706.92%
1-Day Range:
$2.78
$2.92
1-Week Range:
$2.62
$2.98
52-Week Range:
$0.27
$3.45
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
2.80 | 177.03M | 4.39M | -22.40M | -22.79M | -0.5098 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-26 | Initiated | Oppenheimer | Outperform |
| Apr-16-26 | Initiated | B. Riley Securities | Buy |
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Apr-07-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
Equillium Inc. (EQ) Holds Steady at $2.81 – Key Support and Resistance Levels in FocusSystematic Flow - newsline.com
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504 - Insider Monkey
EQ Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesRevenue Miss Report - newsline.com
Equillium COO Christine Zedelmayer sells $42,736 in stock - Investing.com UK
Insider Sell: Stephen Connelly Sells 230,975 Shares of Equillium Inc (EQ) - GuruFocus
Equillium COO Christine Zedelmayer sells $42,736 in stock By Investing.com - Investing.com Nigeria
Equillium (NASDAQ: EQ) Form 144: insider resale activity, 200,000-share sale noted - Stock Titan
Equillium Insider Sold Shares Worth $723,830, According to a Recent SEC Filing - marketscreener.com
Equillium (EQ) COO sells 14,584 shares after exercising stock options - Stock Titan
Equillium (NASDAQ: EQ) CSO Stephen Connelly sells 230,975 shares in open market - Stock Titan
[144] Equillium, Inc. SEC Filing - Stock Titan
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory DiseaseSlideshow (NASDAQ:EQ) 2026-06-03 - Seeking Alpha
Equillium(EQ) Stock Options Chain | Quotes & News - Moomoo
Equillium Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
EQ Reiterated by Roth Capital -- Price Target Maintained at $12 - GuruFocus
B. Riley Securities Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Equillium links AhR activation to miR-124 as EQ504 heads toward Phase 1 - MSN
Is Equillium's AhR/miR-124 Axis the Key to Unlocking Inflammatory Disease Treatment - Kavout
Equillium Insider Sold Shares Worth $267,209, According to a Recent SEC Filing - Moomoo
Leerink Partners upgrades Equillium (EQ) - MSN
Equillium principal accounting officer Tom Penny sells $191,750 in stock By Investing.com - Investing.com Nigeria
Equillium sr. vp and coo Christine Zedelmayer sells $267,209 in shares - Investing.com Nigeria
Equillium principal accounting officer Tom Penny sells $191,750 in stock - Investing.com
Equillium sr. vp and coo Christine Zedelmayer sells $267,209 in shares By Investing.com - Investing.com South Africa
Equillium (EQ) accounting officer sells 65,000 shares under 10b5-1 plan - Stock Titan
Equillium (EQ) director receives 70,000 options at $2.84 exercise price - Stock Titan
Equillium (EQ) director receives grant of 70,000 stock options at $2.84 - Stock Titan
[Form 4] Equillium, Inc. Insider Trading Activity - Stock Titan
Equillium (EQ) COO exercises options and sells 95,833 common shares - Stock Titan
Equillium (EQ) grants director 70,000 options vesting over a year - Stock Titan
Equillium (EQ) director Barbara Troupin receives grant of 70,000 stock options - Stock Titan
Equillium Shareholders Approve Reverse Split and Capital Changes - TipRanks
[8-K] Equillium, Inc. Reports Material Event - Stock Titan
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1 - Barchart.com
A Quick Look at Today's Ratings for Equillium(EQ.US), With a Forecast Between $5 to $12 - Moomoo
Leerink upgrades Equillium stock rating on IBD drug potential - Investing.com UK
Equillium Inc. (EQ) Surges 7.98%: Analyzing the Move and Key Technical LevelsAD Line Divergence - The Legal Advocate
EQ Upgraded by Leerink Partners -- Price Target Raised to $6.00 - GuruFocus
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference - GlobeNewswire
Equillium Raised to Outperform From Market Perform by Leerink Partners - Moomoo
Stifel reiterates Equillium stock rating on AhR biology data - Investing.com UK
Equillium (EQ) Upgraded to Outperform with Target Price Raised t - GuruFocus
Stifel reiterates Equillium stock rating on AhR biology data By Investing.com - Investing.com Nigeria
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Equillium Inc Stock (EQ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zedelmayer Christine | Sr. Vice President and COO |
Jun 05 '26 |
Option Exercise |
0.79 |
14,584 |
11,448 |
77,170 |
| Zedelmayer Christine | Sr. Vice President and COO |
Jun 05 '26 |
Sale |
2.93 |
14,584 |
42,737 |
62,586 |
| Connelly Stephen | President and CSO |
Jun 04 '26 |
Sale |
3.16 |
200,000 |
632,760 |
793,000 |
| Connelly Stephen | President and CSO |
Jun 05 '26 |
Sale |
2.94 |
30,975 |
91,070 |
762,025 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):